Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat + CHOP in Newly Diagnosed PTCL-TFH (SWIFT 02)
NCT06947967Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2025
- Primary completion
- Dec 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tucidinostat in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Progression-Free Survival at 60 months. Started Aug 2025; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06947967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947967.